Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 8/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 8/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 8/20 | 1.00 |
| ▸ | PTGIR | P43119 | 12/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5805033 | 0.95 | PTGIR (1.00) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL5803970 | 0.95 | PTGIR (1.00) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL5802923 | 0.91 | PTGIR (1.00) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL4686704 | 0.91 | PTGIR (1.00) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL5807438 | 0.91 | PTGIR (1.00) | ADRA2AADRA2BADRA2CPTGIR | |
| Hydrochloric Acid SCHEMBL5806185 | 0.90 | PTGIR (0.97) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL5805340 | 0.89 | PTGIR (1.00) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL5802793 | 0.83 | PTGIR (1.00) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL6158355 | 0.83 | PTGIR (0.74) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL5659732 | 0.83 | PTGIR (0.70) | ADRA2AADRA2BADRA2CPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594261-B2 | Use of heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases | SHANGHAI EAST HOSPITAL (EAST HOSPITAL, TONGJI UNIVERSITY SCHOOL OF MEDICINE) (CN) | 2026-04-07 | — | — | US | claimed |
| US-20100331384-A1 | GUANIDINE BASED COMPOUNDS | UNIVERSIDAD DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2010-12-30 | — | — | US | disclosed |
| US-20100331384-A1 | GUANIDINE BASED COMPOUNDS | UNIVERSIDAD DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2010-12-30 | — | — | US | disclosed |
| WO-2009080818-A2 | GUANIDINE BASED COMPOUNDS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594261-B2 | Use of heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases | TNNT2, TNNI3, CCNO | ADRA2A 317/4885ADRA2B 191/4885ADRA2C 148/4885 |
| US-20100331384-A1 | GUANIDINE BASED COMPOUNDS | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885ADRA2B 6/4885ADRA2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.